GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmsynthez PJSC (MIC:LIFE) » Definitions » Debt-to-Revenue

Pharmsynthez PJSC (MIC:LIFE) Debt-to-Revenue : 2.21 (As of Jun. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Pharmsynthez PJSC Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Pharmsynthez PJSC's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was ₽720.2 Mil. Pharmsynthez PJSC's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was ₽40.8 Mil. Pharmsynthez PJSC's annualized Revenue for the quarter that ended in Jun. 2023 was ₽344.9 Mil. Pharmsynthez PJSC's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 was 2.21.


Pharmsynthez PJSC Debt-to-Revenue Historical Data

The historical data trend for Pharmsynthez PJSC's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmsynthez PJSC Debt-to-Revenue Chart

Pharmsynthez PJSC Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 1.51 1.68 1.62 1.96

Pharmsynthez PJSC Semi-Annual Data
Dec11 Jun13 Dec13 Jun14 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.64 1.45 2.17 2.21

Competitive Comparison of Pharmsynthez PJSC's Debt-to-Revenue

For the Biotechnology subindustry, Pharmsynthez PJSC's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmsynthez PJSC's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmsynthez PJSC's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Pharmsynthez PJSC's Debt-to-Revenue falls into.



Pharmsynthez PJSC Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Pharmsynthez PJSC's Debt-to-Revenue for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(703.632 + 41.772) / 379.67
=1.96

Pharmsynthez PJSC's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(720.246 + 40.771) / 344.92
=2.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2023) Revenue data.


Pharmsynthez PJSC Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pharmsynthez PJSC's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmsynthez PJSC (MIC:LIFE) Business Description

Traded in Other Exchanges
N/A
Address
150 Engelsa Prospect, St. Petersburg, RUS, 194358
Pharmsynthez PJSC is a pharmaceutical company developing new medications, technologies of drugs for organ-specific delivery and innovative methods of manufacture for pharmaceutical ingredients. The company is engaged in the research and development, production and sales of officinal medicines (original OM) and active pharmaceutical ingredients (API).

Pharmsynthez PJSC (MIC:LIFE) Headlines

No Headlines